forum

AUROPHARMA Share Price Target

Aurobindo Pharma Ltd.
Sector: Pharmaceuticals and health care
... Read more
AUROPHARMA Share Price *
618.2 +1.5 (0.24%)
* (quote may be delayed)
AUROPHARMA Share Price Forecast - Consensus
No. of reports in last year
29
No. of analysts
13
Average Consensus Forecast
850.07
Consensus Potential
26.61%

AUROPHARMA Share Price Target - Broker Reports - 2019

Axis Direct
19-Aug-19
Price @ Call: 602.15
Target: 662
BUY
Management guided for 40 new launches in next nine month in FY20E, which will drive the overall US revenue growth. ARBP expects significant growth opportunities from new injectable launches, scaling-up of existing business, and traction in OTC business. ARBP also expects ~20-30 ANDAs approvals in FY20. With robust product launches and scale-up in existing portfolio, we expect US generic business to grow ~15-16% CAGR over next two years.We maintain a BUY with a target price of Rs. 662.
... Read more

Prabhudas Lilladher
9-Aug-19
Price @ Call: 598
Target: 715
BUY
ARBP currently trades at PE 12.9x of FY20E and 11.7x of FY21E. While valuation remains attractive for new investment, we believe ARBP to remain at discount vs. peers due to its large contribution from US and zero presence in India formulations. Currently, 1-year forward earnings from US values at PE 9-12x, similar to global peers while earnings from India formulations trades at PE 15-16x due to better risk-reward matrix. We maintain ‘BUY’, while decreases TP to Rs715 (with PE 14x of FY21E earnings) from Rs952.
... Read more

Nirmal Bang
8-Aug-19
Price @ Call: 586.42
Target: 868
BUY
Sandoz transaction closure expected shortly
The key driver for APL henceforth will be the integration of Sandoz oral and dermatology business acquisition, which is expected to be the immediately earnings-accretive. As the acquired business from Sandoz includes some rapidly declining opportunities, timely closure of the transaction is critical. Earnings from the acquired operations are expected to decline over time, but in the meantime APL can aggressively invest in restructuring costs to ensure that the margins remain favourable. To ensure growth in the long run, APL continues to build and invest in capabilities in alternate dosage forms like respiratory inhalers, peptides, vaccines and depot injectables. In the near to medium term, incremental competition for Ertapenem generics is the key risk to earnings. We maintain Buy on the stock with a target price (TP) of Rs868 based on 16x March FY21E EPS.
... Read more

ICICIdirect.com
8-Aug-19
Price @ Call: 586.42
Target: 735
BUY
In the US, the company continues to grow on new launches and injectables. The management expects strong growth in injectables and other new launches to drive US sales and margins. Acquisitions of Sandoz and spectrum augurs well as this offers a footprint in the derma and oncology branded segment in the US and in a way fills the portfolio gap. There will be significant debt addition nonetheless. However, looking at the broader picture of synergy and earlier history of successful acquisitions, we believe the company is well poised to manage this added burden. Aurobindo possesses one of the best enduring ecosystems among peers (vertically integrated model, lower product concentration). We arrive at our target price of | 735 based on 12x FY21E EPS of | 61.2.
... Read more

Sharekhan
8-Aug-19
Price @ Call: 586.42
Target: 710
HOLD
Although existing businesses may not be affected by the warning letter issued(for Unit- XI), approval for future filings done from these plants couldget delayed. Moreover, remediation and site transfer-related costs and integration of acquisitions could stress the company’s margins in the near term. However, on the back of strong quarterly numbers, we maintain our earnings estimates for FY2020E and FY2021E. Weexpect the company to report sales and profit CAGRs of 29% and 22%,respectively, in the next two years. We feel the uncertainty related to regulatory hurdles at various units will weigh on the stock (until resolved successfully). We would like to monitor the sustainability of Q1 performance before taking a constructive view to upgrade the stock rating. Thus we maintain our Hold rating on the stock with an unchanged price target (PT) of Rs. 710.
... Read more

Sharekhan
28-Jun-19
Price @ Call: 613.72
Target: 710
HOLD
Downgrade to Hold with downward revised PT of Rs 710. With a pattern emerging with the issues at all the API units, threat of warning letters for its other units cannot be ruled out. Although impact on existing businesses can be ruled out because of these developments, approval for future filings from these plants are likely to get delayed. Also, the remediation and site transfer related costs are likely to put the company’s near term margins under pressure. The company is considering site transfer as a precautionary measure. Thus we have revised downwards our sales/earnings estimates for FY2020/ FY2021 by 4%/13% and 7%/14% respectively. We expect the company to report sales and profit CAGR of 29% and 22%, respectively, over the next two years. The uncertainty related to regulatory hurdles at various units will weigh on the stock (until resolved successfully). Thus we downgrade our recommendation to Hold with downward revised price target of Rs 710.
... Read more

ICICIdirect.com
21-Jun-19
Price @ Call: 595.79
Target: 705
BUY
We reduce FY20 EPS by 2% and FY21 EPS by 4% on the back of higher regulatory and other related costs and possible delay in some product launches. More than earnings, the impact will be higher on the sentiments. Accordingly, we reduce earnings multiple to 13x (from 15x) mainly due to regulatory overhang. We arrive at our new target price of Rs 705 based on 13x of FY21 EPS of 54.3.
... Read more

Nirmal Bang
31-May-19
Price @ Call: 683.04
Target: 868
BUY
To ensure growth in the long run, APL continues to build and invest in capabilities in alternate dosage forms like respiratory inhalers, peptides, vaccines, and depot injectables. In the near to mid-term, incremental competition in Renvela suspension generic and Ertapenem generics the key risk to earnings. We have updated our estimates to incorporate a delay in Sandoz portfolio integration which will have an impact on our FY20EPS. Based on our revised forecasts, we maintain Buy on the stock with a revised target price of Rs868 (from Rs866 earlier) based on 16x March FY21E EPS.
... Read more

Reliance Securities
30-May-19
Price @ Call: 692.36
Target: 860
BUY
we expect strong ramp-up in operating performance of Europe business – which has already achieved double-digit expansion in EBITDA margin – and healthy growth in the US business backed by new launches, ramp-up in injectable business (US$66mn in 4QFY19 vs. US$50mn in 2QFY19 and US$35mn in 4QFY18; FY18: US$163mn), strong products pipeline (138 pending for approval) and diversified product-mix. At CMP, the stock trades at a discount to its peers owing to higher leverage. Notably, ARBP has reduced core net debt by US$75mn in FY19 from earlier guidance of US$50mn. We maintain our BUY recommendation on the stock with a Target Price of Rs860.
... Read more

ICICIdirect.com
29-May-19
Price @ Call: 676
Target: 850
BUY
In the US, the company continues to grow on new launches and injectables. The management expects strong growth in injectables and other new launches to drive the US sales and margins. Acquisitions of Sandoz and spectrum augurs well as this offers a footprint in the derma and oncology branded segment in the US and in a way fills the portfolio gap. There will be significant debt addition nonetheless but looking at the broader picture of synergy and earlier history of successful acquisitions, we believe the company is well poised to manage this added burden. Aurobindo possesses one of the best enduring ecosystems among peers (vertically integrated model, lower product concentration). We arrive at our target price of | 850 based on 15x FY21E EPS of Rs 56.6.
... Read more

Prabhudas Lilladher
20-Mar-19
Price @ Call: 777.5
Target: 952
BUY

Angel Broking
14-Mar-19
Price @ Call: 765
Target: 890
BUY

Edelweiss
11-Feb-19
Price @ Call: 761
Target: 780
HOLD

Nirmal Bang
11-Feb-19
Price @ Call: 761
Target: 866
ACCUMULATE

Motilal Oswal
11-Feb-19
Price @ Call: 761
Target: 940
BUY

Prabhudas Lilladher
11-Feb-19
Price @ Call: 761
Target: 952
BUY

HDFC Securities
11-Feb-19
Price @ Call: 761
Target: 800
NEUTRAL

Angel Broking
8-Feb-19
Price @ Call: 766.68
Target: 890
BUY

ICICIdirect.com
8-Feb-19
Price @ Call: 774
Target: 915
BUY

Phillip Capital
21-Jan-19
Price @ Call: 779.77
Target: 920
BUY

Angel Broking
21-Jan-19
Price @ Call: 779.77
Target: 890
BUY

Motilal Oswal
18-Jan-19
Price @ Call: 774.25
Target: 940
BUY

Prabhudas Lilladher
10-Jan-19
Price @ Call: 768.68
Target: 994
BUY

AUROPHARMA Share Price Target - Broker Reports - 2018

Geojit Financial Services
27-Dec-18
Price @ Call: 719.51
Target: 811
BUY

HDFC Securities
30-Nov-18
Price @ Call: 805.24
Target: 840
NEUTRAL

Angel Broking
17-Nov-18
Price @ Call: 783.05
Target: 855
ACCUMULATE

HDFC Securities
15-Nov-18
Price @ Call: 784.33
Target: 875
BUY

Prabhudas Lilladher
13-Nov-18
Price @ Call: 798.3
Target: 909
BUY

Swastika Investmart
6-Nov-18
Price @ Call: 778.5
Target: 950
BUY

Centrum
11-Sep-18
Price @ Call: 797.16
Target: 1270
BUY

Arihant Capital Markets
11-Sep-18
Price @ Call: 797.16
Target: 910
ACCUMULATE

ICICIdirect.com
10-Sep-18
Price @ Call: 800.57
Target: 915
BUY

Prabhudas Lilladher
7-Sep-18
Price @ Call: 759.55
Target: 909
BUY

Motilal Oswal
7-Sep-18
Price @ Call: 759.55
Target: 910
BUY

Centrum
14-Aug-18
Price @ Call: 623.95
Target: 1010
BUY

Kotak Securities
13-Aug-18
Price @ Call: 610.15
Target: 640
BUY

HDFC Securities
13-Aug-18
Price @ Call: 610.15
Target: 691
BUY

Arihant Capital Markets
13-Aug-18
Price @ Call: 616.59
Target: 686
BUY

Prabhudas Lilladher
10-Aug-18
Price @ Call: 605.6
Target: 909
BUY

Motilal Oswal
10-Aug-18
Price @ Call: 605.6
Target: 750
BUY

Sharekhan
10-Aug-18
Price @ Call: 605.6
Target: 725
BUY

ICICIdirect.com
10-Aug-18
Price @ Call: 605.6
Target: 685
BUY

Prabhudas Lilladher
1-Aug-18
Price @ Call: 597.2
Target: 909
BUY

Angel Broking
4-Jul-18
Price @ Call: 627.05
Target: 770
BUY

Edelweiss
31-May-18
Price @ Call: 560.62
Target: 630
HOLD

Motilal Oswal
30-May-18
Price @ Call: 579.5
Target: 750
BUY

Prabhudas Lilladher
21-May-18
Price @ Call: 578.1
Target: 909
BUY

Investec Securities
17-May-18
Price @ Call: 602.65
Target: 760
BUY

Arihant Capital Markets
11-Apr-18
Price @ Call: 607.9
Target: 728
ACCUMULATE

Prabhudas Lilladher
5-Mar-18
Price @ Call: 623
Target: 909
BUY

Axis Direct
16-Feb-18
Price @ Call: 591.13
Target: 700
BUY

Prabhudas Lilladher
9-Feb-18
Price @ Call: 601.9
Target: 909
BUY

Motilal Oswal
9-Feb-18
Price @ Call: 601.9
Target: 820
BUY

AUROPHARMA Share Price Target - Broker Reports - 2017

Prabhudas Lilladher
28-Nov-17
Price @ Call: 719.25
Target: 877
BUY

Khambatta Securities
23-Nov-17
Price @ Call: 698.8
Target: 904
BUY

Centrum
22-Nov-17
Price @ Call: 709.4
Target: 1030
BUY

Motilal Oswal
11-Nov-17
Price @ Call: 760.75
Target: 900
BUY

Nirmal Bang
10-Nov-17
Price @ Call: 760.75
Target: 818
ACCUMULATE

Geojit Financial Services
17-Oct-17
Price @ Call: 757.6
Target: 865
BUY

Powermywealth.com
10-Oct-17
Price @ Call: 730.3
Target: 940
HOLD

Geojit Financial Services
1-Sep-17
Price @ Call: 725.25
Target: 817
BUY

Khambatta Securities
23-Aug-17
Price @ Call: 699.82
Target: 800
BUY

Axis Direct
18-Aug-17
Price @ Call: 703.5
Target: 825
BUY

Motilal Oswal
11-Aug-17
Price @ Call: 683
Target: 850
BUY

ICICIdirect.com
11-Aug-17
Price @ Call: 683
Target: 745
HOLD

Axis Direct
24-Jul-17
Price @ Call: 734
Target: 850
BUY

Motilal Oswal
19-Jul-17
Price @ Call: 767
Target: 850
BUY

Prabhudas Lilladher
19-Jul-17
Price @ Call: 733.75
Target: 940
BUY

HDFC Securities
14-Jul-17
Price @ Call: 735.56
Target: 760
BUY

Nirmal Bang
29-Jun-17
Price @ Call: 670.6
Target: 704
BUY

Sharekhan
28-Jun-17
Price @ Call: 670.3
Target: 735
HOLD

Centrum
6-Jun-17
Price @ Call: 593
Target: 970
BUY

Khambatta Securities
31-May-17
Price @ Call: 580.15
Target: 808
BUY

Reliance Securities
30-May-17
Price @ Call: 582
Target: 700
BUY

HDFC Securities
30-May-17
Price @ Call: 580
Target: 740
BUY

Edelweiss
30-May-17
Price @ Call: 580
Target: 640
HOLD

ICICIdirect.com
30-May-17
Price @ Call: 557.6
Target: 753
BUY

Motilal Oswal
4-May-17
Price @ Call: 592
Target: 900
BUY

Motilal Oswal
6-Mar-17
Price @ Call: 668
Target: 915
BUY

Geojit Financial Services
23-Feb-17
Price @ Call: 675
Target: 801
BUY

Centrum
21-Feb-17
Price @ Call: 665
Target: 1110
BUY

Axis Direct
16-Feb-17
Price @ Call: 646.02
Target: 800
BUY

Khambatta Securities
13-Feb-17
Price @ Call: 660
Target: 917
BUY

ICICIdirect.com
13-Feb-17
Price @ Call: 679
Target: 965
BUY

Motilal Oswal
10-Feb-17
Price @ Call: 706
Target: 1050
BUY

ICICIdirect.com
11-Jan-17
Price @ Call: 695
Target: 1100
BUY

Motilal Oswal
9-Jan-17
Price @ Call: 693
Target: 1050
BUY

AUROPHARMA Share Price Target - Broker Reports - 2016

Motilal Oswal
16-Dec-16
Price @ Call: 691
Target: 1050
BUY

Reliance Securities
17-Nov-16
Price @ Call: 708
Target: 991
BUY

Angel Broking
16-Nov-16
Price @ Call: 733
Target: 877
BUY

Axis Direct
16-Nov-16
Price @ Call: 772
Target: 940
BUY

Prabhudas Lilladher
15-Nov-16
Price @ Call: 733
Target: 943
BUY

Centrum
15-Nov-16
Price @ Call: 772
Target: 1060
BUY

ICICIdirect.com
15-Nov-16
Price @ Call: 772
Target: 1100
BUY

Axis Direct
7-Oct-16
Price @ Call: 865
Target: 970
BUY

Reliance Securities
25-Aug-16
Price @ Call: 794.75
Target: 981
BUY

Angel Broking
25-Aug-16
Price @ Call: 788
Target: 877
ACCUMULATE

IIFL
25-Aug-16
Price @ Call: 798.6
Target: 1030
BUY

Axis Direct
25-Aug-16
Price @ Call: 796.38
Target: 970
BUY

ICICIdirect.com
24-Aug-16
Price @ Call: 736
Target: 1055
BUY

Khambatta Securities
24-Aug-16
Price @ Call: 788
Target: 932
BUY

Motilal Oswal
30-Jun-16
Price @ Call: 745.35
Target: 1100
BUY

Shahina Mukadam
22-Jun-16
Price @ Call: 718.05
Target: 800
HOLD

Prabhudas Lilladher
3-Jun-16
Price @ Call: 790.82
Target: 943
BUY

ICICIdirect.com
1-Jun-16
Price @ Call: 770
Target: 990
BUY

Motilal Oswal
31-May-16
Price @ Call: 786
Target: 1100
BUY

Prabhudas Lilladher
31-May-16
Price @ Call: 786
Target: 943
BUY

Nirmal Bang
7-Apr-16
Price @ Call: 762.15
Target: 894
BUY

  • AUROPHARMA - Share Price Target Potential

    keyboard_arrow_down
    BrokerageTargetPotential
    Axis Direct6626.84%
    Prabhudas Lilladher71513.75%
    Nirmal Bang86828.95%
    ICICIdirect.com73516.10%
    Sharekhan71013.14%